Biphenyl compounds useful as muscarinic receptor antagonists

Patent metadata

Field	Value
Publication number	US-9452161-B2
Application number	US-201615016528-A
Country	US
Kind code	B2
Filing date	Feb 5, 2016
Priority date	Mar 11, 2004
Publication date	Sep 27, 2016
Grant date	Sep 27, 2016

Abstract

This invention provides compounds of formula I:

wherein a, b, c, d, m, n, p, s, t, W, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

First claim

What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable dry powder excipient and biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of claim 1 , wherein the composition further comprises an agent selected from β 2 adrenergic receptor agonists, steroidal anti-inflammatory agents, phosphodiesterase-4 inhibitors, or pharmaceutically acceptable salts thereof, and combinations thereof.

3. The pharmaceutical composition of claim 2 , wherein the composition comprises a β 2 adrenergic receptor agonist and a steroidal anti-inflammatory agent, or pharmaceutically acceptable salts thereof.

4. The composition of claim 1 , wherein the excipient is lactose or starch.

5. The composition of claim 1 , wherein the excipient is lactose having a particle size between about 1 μm and about 100 μm.

6. The composition of claim 2 , which comprises a β 2 adrenergic receptor agonist or a pharmaceutically acceptable salt thereof.

7. The composition of claim 6 , wherein the β 2 adrenergic receptor agonist is formoterol or a pharmaceutically acceptable salt thereof.

8. The composition of claim 2 , which comprises a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt thereof.

9. The composition of claim 2 , which comprises a phosphodiesterase-4 inhibitor or a pharmaceutically acceptable salt thereof.

Assignees

• Mammen Mathai
• Ji Yuhua
• Mu Yongqi
• Husfeld Craig
• Li Li
• Theravance Biopharma R&D Ip Llc

Inventors

• Mammen Mathai
• Ji Yuhua
• Mu Yongqi
• Husfeld Craig
• Li Li

Classifications

• A61P9/06

  Antiarrhythmics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title